Program
GSK3772701
A development code. Also written as “GSK3772701 600 mg”, “GSK3772701 900 mg” and “GSK3772701 150 mg”.
In GlaxoSmithKline's pipeline, P. falciparum whole cell inhibitor
. Its studies are mostly in Malaria, Falciparum, led by GlaxoSmithKline.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 21 open or running | phase 2since Apr 16, 2026 | Apr 16, 2026 | Oct 8, 2027phase 2 · NCT07545681 |
- Named in GlaxoSmithKline’s own pipeline as
GSK3772701
, phase 1, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 16, 2026First study: phase 2 study in Malaria, FalciparumFirst studyNCT07545681 · 70 planned · Gabon, Uganda
- Jun 19, 2026Phase 1 study in Malaria, FalciparumNCT07670377 · 20 enrolled · United States
Ahead
- Oct 8, 2027Primary completion: phase 2 study in Malaria, FalciparumNCT07545681
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“P. falciparum whole cell inhibitor”the company's pipeline, read by Claude · source
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07670377Malaria, Falciparum · United States | 1 | Completed | Aug 24, 2026 | 20 |
| NCT07545681Malaria, Falciparum · Gabon, Uganda | 2 | Recruiting | Oct 8, 2027 | 70 |
How it is read
Names in the registry
- “GSK3772701 600 mg”, 1 entry
- “GSK3772701 900 mg”, 1 entry
- “GSK3772701 150 mg”, 1 entry
- “GSK3772701 400 mg”, 1 entry
- “GSK3772701 50 mg”, 1 entry
Codes read as this program: GSK3772701.
Conditions, from the studies’ own filings
- Malaria, Falciparum, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.